Skip to main content

Table 3 Comparison of hepatocellular carcinoma versus cholangiocarcinoma after propensity score matching

From: Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis

Variable HCC (n = 43) CC (n = 51) p value
Male 28 (65.1) 33 (64.7) 0.213
Age (years) 59 (35–81) 60 (35–80) 0.967
Smoking 13 (30.2) 8 (15.7) 0.092
Alcohol use 11 (25.6) 4 (7.8) 0.099
HBV positive 21 (48.8) 26 (51.0) 0.836
HCV positive 9 (20.9) 18 (35.3) 0.125
Total bilirubin 0.85 ± 0.33 0.94 ± 0.46 0.241
Albumin 4.1 ± 0.4 4.2 ± 0.3 0.498
INR 1.05 ± 0.06 1.05 ± 0.12 0.912
Cirrhosis 3 (7.0) 6 (11.8) 0.432
Child–Pugh class A 39 (90.7) 51 (100) 0.058
Edmondson–Steiner Grades, I–II 5 (11.6) 12 (23.5) 0.379
Tumor size 5.7 ± 3.6 5.3 ± 2.4 0.596
Tumor size ≥ 5 cm 19 (44.4) 23 (52.3) 0.450
Tumor number (≥ 2) 1 (2.3) 2 (4.5) 0.570
AFP (ng/mL) ≥ 200 8 (18.6) 3 (5.9) 0.061
ICG% 9.2 ± 4.7 9.6 ± 5.5 0.686
Operative margin > 1 cm 24 (55.8) 30 (58.8) 0.749
Major hepatectomy 23 (53.4) 35 (68.6) 0.258
Microvascular invasion 9 (20.9) 8 (15.7) 0.510
Macrovascular invasion 6 (13.9) 1 (1.9) 0.057
Lympho nodules metastasis 2 (4.6) 8 (15.7) 0.062
Distal metastasis 0 (0) 3 (5.9) 0.106
AJCC stage, I–II 23 (60.4) 36 (70.5) 0.163
Antiviral therapy 18 (41.8) 25 (49.0) 0.186
Recurrence 16 (37.2) 6 (11.8) 0.004
Mortality 13 (30.2) 27 (52.9) 0.027
Follow up times (months) 61 (1–98) 26 (1–85) < 0.0001
  1. Data are presented as the median (range) or number (percentage)
  2. HBV Hepatitis B virus, HCV hepatitis C virus, INR international normalized ratio, AFP alpha-fetoprotein, ICG indocyanine green, AJCC American Joint Committee on Cancer